These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17575132)

  • 1. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
    Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
    Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
    Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
    Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM; Ren R
    Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
    Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
    Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
    Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
    Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM; Ren R
    Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
    Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
    Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
    Cuenco GM; Nucifora G; Ren R
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3.
    Khanna-Gupta A; Lopingco MC; Savinelli T; Zibello T; Berliner N; Perkins AS
    Oncogene; 1996 Feb; 12(3):563-9. PubMed ID: 8637713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
    Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
    Mitani K
    Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation.
    Wimmer K; Vinatzer U; Zwirn P; Fonatsch C; Wieser R
    Biochem Biophys Res Commun; 1998 Nov; 252(3):691-6. PubMed ID: 9837768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
    Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
    Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the RUNX1-EVI1 fusion gene in leukemogenesis.
    Maki K; Yamagata T; Mitani K
    Cancer Sci; 2008 Oct; 99(10):1878-83. PubMed ID: 19016745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
    Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.